Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.68
+0.10006.33%
Pre-market: 1.680.00000.00%07:23 EDT
Volume:648.56K
Turnover:1.07M
Market Cap:221.76M
PE:-3.42
High:1.69
Open:1.62
Low:1.59
Close:1.58
52wk High:2.37
52wk Low:1.33
Shares:132.00M
Float Shares:61.84M
Volume Ratio:0.34
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4909
EPS(LYR):-0.3086
ROE:-36.05%
ROA:-20.53%
PB:1.28
PE(LYR):-5.44

Loading ...

Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Mar 30

Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 27

Inhibikase Therapeutics FY2025 net loss widens 75.39% to $48 million; R&D expenses climb 73.13% to $30 million

Reuters
·
Mar 27

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Benzinga
·
Mar 27

Press Release: Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Dow Jones
·
Mar 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
Mar 23

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20

Inhibikase Therapeutics Initiated at Buy by Ladenburg Thalmann

Dow Jones
·
Mar 04

Ladenburg Thalmann Initiates Inhibikase Therapeutics at Buy

MT Newswires Live
·
Mar 04

Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001

TIPRANKS
·
Feb 24

Analysts’ Top Healthcare Picks: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD)

TIPRANKS
·
Feb 24

BofA Securities Initiates Coverage on Inhibikase Therapeutics With Buy Rating, $6 Price Target

MT Newswires Live
·
Jan 21

Inhibikase Therapeutics Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $6

THOMSON REUTERS
·
Jan 21

Inhibikase Therapeutics Initiated at Buy by B of A Securities

Dow Jones
·
Jan 21

Inhibikase Therapeutics initiated with a Buy at BofA

TIPRANKS
·
Jan 21

Inhibikase Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Dec 26, 2025

Inhibikase Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $8

THOMSON REUTERS
·
Dec 26, 2025

Inhibikase Therapeutics Inc - Files Prospectus Supplement for Atm Program - SEC Filing

THOMSON REUTERS
·
Dec 20, 2025